Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3668215 | 1.00 | HRH3 (0.51) | HRH3LTA4HAPPKCNH2KDM4E | |
| SCHEMBL3672172 | 0.75 | ALDH1A1 (0.49) | HRH3KDM4ENPC1RAB9A | |
| SCHEMBL3672168 | 0.75 | ALDH1A1 (0.49) | HRH3KDM4ENPC1RAB9A | |
| SCHEMBL3665011 | 0.74 | HRH3 (0.45) | HRH3KCNH2 | |
| SCHEMBL3665012 | 0.74 | HRH3 (0.45) | HRH3KCNH2 | |
| SCHEMBL28563701 | 0.71 | KDM4E (0.66) | APPKDM4ENPC1RAB9A | |
| SCHEMBL3666225 | 0.71 | HRH3 (0.48) | HRH3KCNH2 | |
| SCHEMBL3666222 | 0.71 | HRH3 (0.48) | HRH3KCNH2 | |
| SCHEMBL3668162 | 0.71 | HRH3 (0.48) | HRH3 | |
| SCHEMBL3668166 | 0.71 | HRH3 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | claimed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | claimed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | CYP11B2, CYP11B1, CYP4B1 | HRH3 2630/4885LTA4H 505/4885APP 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.